Search MassTLC
Sign In

Sign In securely

Create Your Free Profile

MassTLC Calendar


Get email updates on upcoming events and
new content!




Content Library: Member News

Imprivata Launches New Product to Enable Major Shift to e-Prescribing of Controlled Substances

Monday, February 9, 2015   (0 Comments)
Posted by: Rachael LaMalva
Share |

Imprivata Launches New Product to Enable Major Shift to Electronic Prescribing of Controlled Substances 

Imprivata Confirm ID, the First Comprehensive Product that Simplifies Adoption of Regulatory Requirements for EPCS, Helps Providers Address Inefficiencies and Potential Fraud Caused by Paper-Based Prescriptions

Lexington, Mass.—February 9, 2015—Imprivata® (NYSE: IMPR), the healthcare IT security company, today launched Imprivata Confirm ID™, the industry’s first comprehensive product to enable a major shift from paper to electronic prescribing of controlled substances (EPCS). Imprivata Confirm ID simplifies adoption of regulatory requirements for EPCS, helping care providers address the workflow inefficiencies and potential for fraud caused by paper-based prescriptions. Imprivata Confirm ID also integrates with leading electronic health records (EHRs) and offers multiple DEA-approved two-factor authentication options for prescription signing, giving providers a single, consistent e-prescribing experience for all medications. 

“The volume of prescriptions for controlled substances, which are primarily paper-based, continues to rise, creating clinical workflow inefficiencies, decreasing patient satisfaction, and increasing the risk of drug diversion and fraud. At the same time, prescription drug addiction and abuse is a growing public health epidemic,” said Omar Hussain, president and CEO of Imprivata. “The industry is looking for technologies that address this inefficiency and potential for fraud while enhancing patient care. Imprivata has worked closely with customers, leading EHR vendors, and other partners to deliver Imprivata Confirm ID, a comprehensive, integrated product that simplifies the adoption of regulatory requirements for EPCS and enables fast, secure e-prescribing of controlled substances.”

Imprivata Confirm ID is the industry’s first product that offers provider identity-proofing, supervised enrollment of providers’ approved credentials, support for multiple DEA-approved two-factor authentication modalities for prescription signing, and comprehensive auditing and reporting tools. Imprivata Confirm ID also simplifies EPCS by integrating directly into the e-prescribing workflows of leading EHRs and giving providers the necessary flexibility to leverage the two-factor authentication options that meet all their prescribing workflow requirements. This increases efficiency and provider satisfaction while maintaining security, which minimizes the potential for fraud or drug diversion.

“EPCS plays an important role in addressing America’s opioid abuse epidemic by eliminating the exposure of a physician’s signature and DEA number, which greatly reduces the risk of drug diversion or fraud,” said Michael A. Lee, MD, Director of Clinical Informatics at Atrius Health. “EPCS also decreases errors and removes cumbersome workflows associated with high-cost, hand-written prescriptions, which increases productivity for prescribers and safety and convenience for patients. For providers working within a highly regulated environment, tools like this that can help achieve compliance, increase efficiency, and improve patient outcomes are invaluable.” 

Imprivata Confirm ID supports fingerprint biometric identification and one-time-password (OTP) tokens, giving providers the option to use the two-factor authentication modalities that best fit their prescribing workflows. Imprivata Confirm ID automates the presentation of the authentication modality, prompting prescribers with only the options available and allowed for EPCS. This creates a single signing experience for all medications, which improves provider productivity and increases patient satisfaction.

Imprivata will host a webinar titled “Introducing Imprivata Confirm ID: Fast, Secure Signing for e-Prescribing of Controlled Substances” on Tuesday, February 17, 2015 at 2 p.m. EST. To learn more about Imprivata Confirm ID and the DEA requirements for EPCS, register for the webinar at:


About Imprivata

Imprivata (NYSE: IMPR), the healthcare IT security company, is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit


Media Contacts:                                  

John Hallock

Dan Borgasano

Investor Contact:
Bob East / Asher Dewhurst
Westwicke Partners

                                                                                                   THANK YOU TO OUR GLOBAL SPONSORS                                                       

















Board of Directors
In the News
Contact Us
Member Directory
Tech Company
IT Department
Join Now
Renew Now
Annual Meeting
Boston TechJam
Innovation unConference
Leadership Awards
MassTLC Events
Community Events
Big Data
CXO Series
Internet of Things
Healthcare & Life Sciences
Sales & Marketing
Software Dev
Workforce Dev
Ed Foundation
K-12 Initiatives

Affiliate Directory

Content Library
Job Board
More Opportunities
Get Involved